Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with
 overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia
 (BPH) who previously completed treatment in Study URO-901-3005 (NCT03902080).
Inclusion Criteria:

 -  Participant has completed participation of the 24-week double-blind treatment period
 in Study URO-901-3005 (NCT03902080) and demonstrated compliance with the study
 procedures and study medication schedule in the opinion of the investigator.

 -  Participant is capable of giving written informed consent, which includes compliance
 with the requirements and restrictions listed in the consent form.

 -  Participant has the ability to continue to receive a stable dose of Benign Prostatic
 Hyperplasia (BPH) treatment with either a) alpha blocker monotherapy or b) alpha
 blocker +5-ARI.

 -  In the opinion of the investigator, the participant is able and willing to comply with
 the requirements of the protocol, including completing study questionnaires and the
 Bladder Diary.

 Exclusion Criteria:

 -  Participant experienced any Serious Adverse Event in Study URO-901-3005 that was
 reported as "possibly or probably related" to study treatment by the investigator.

 -  Participant is using any prohibited medications

 -  Participant has uncontrolled hyperglycemia (defined as fasting blood glucose >150
 milligrams per deciliter [mg/dL] or 8.33 millimoles per Liter [mmol/L] and/or
 non-fasting blood glucose >200 mg/dL or 11.1 mmol/L) based on most recent available
 lab results in Study URO-901-3005 or uncontrolled in the opinion of the investigator.

 -  Participant has uncontrolled hypertension (systolic blood pressure of ≥180 millimeters
 of mercury [mmHg] and/or diastolic blood pressure of ≥100 mmHg) or has a resting heart
 rate (by pulse) >100 beats per minute.

 -  Participant has systolic blood pressures ≥160 mmHg but <180 mmHg, unless deemed by the
 investigator as safe to proceed in this study and able to complete the study per
 protocol.

 -  Participant has current evidence of any clinically significant condition, therapy, lab
 abnormality, or other circumstances that might, in the opinion of the investigator,
 confound the results of the study, interfere with the participant's ability to comply
 with study procedures, or make participation in the study not in the participant's
 best interest.